title: Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma.
authors.forename: Marco
authors.initials: M
authors.lastname: Herling
authors.forename: George Z
authors.initials: GZ
authors.lastname: Rassidakis
authors.forename: Theodoros P
authors.initials: TP
authors.lastname: Vassilakopoulos
authors.forename: L Jeffrey
authors.initials: LJ
authors.lastname: Medeiros
authors.forename: Andreas H
authors.initials: AH
authors.lastname: Sarris
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D003131:Combined Modality Therapy; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D005260:Female; D015967:Gene Expression Regulation, Viral; D006689:Hodgkin Disease / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D014763:Viral Matrix Proteins / Q000096:biosynthesis*
chemical_list: C037662:EBV-associated membrane antigen, Epstein-Barr virus; D014763:Viral Matrix Proteins